持续动脉内化疗用于降期局部晚期口腔 commissure 癌。 （注：这里“commissure”可能是医学术语中特定的解剖部位，比如口角联合处等，具体翻译需结合医学背景准确理解）
Continuous intra-arterial chemotherapy for downstaging locally advanced oral commissure carcinoma.
作者信息
Wu Chih-Fung, Chang Kao-Ping, Huang Chih-Jen, Chen Chun-Ming, Chen Ching-Yi, Steve Lin Chen-Lung
机构信息
Department of Surgery, College of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
出版信息
Head Neck. 2014 Jul;36(7):1027-33. doi: 10.1002/hed.23408. Epub 2013 Sep 18.
BACKGROUND
The purpose of this study was to assess the usefulness, safety, and efficacy of intra-arterial (IA) infusion chemotherapy for patients with locally advanced oral commissure cancer.
METHODS
Twenty-one patients with stages III and IV squamous cell carcinoma involving the mouth angle were recruited. Methotrexate (MTX; 50 mg/day) was continuously infused into the external carotid artery for a mean period of 8 days, followed by weekly IA bolus of 25 mg MTX for a mean period of 10 weeks.
RESULTS
Thirteen patients (62%) achieved a complete response (CR) and 7 patients (33%) had a partial response (PR). At a median follow-up of 69 months, the estimated 1-year, 3-year, and 5-year survival rates of the patients with CR versus PR were 100% versus 57%, 92% versus 43%, and 80% versus 43%, respectively.
CONCLUSION
Our data demonstrate that continuous IA chemotherapy could achieve a competitive acceptable survival rate and improved locoregional control of advanced oral commissure cancer.
背景
本研究旨在评估动脉内（IA）灌注化疗对局部晚期口角癌患者的有效性、安全性和疗效。
方法
招募了21例累及口角的III期和IV期鳞状细胞癌患者。将甲氨蝶呤（MTX；50mg/天）持续注入颈外动脉，平均持续8天，随后每周进行一次25mg MTX的动脉内推注，平均持续10周。
结果
13例患者（62%）达到完全缓解（CR），7例患者（33%）有部分缓解（PR）。在中位随访69个月时，CR患者与PR患者的估计1年、3年和5年生存率分别为100%对57%、92%对43%和80%对43%。
结论
我们的数据表明，持续动脉内化疗可实现具有竞争力的可接受生存率，并改善晚期口角癌的局部区域控制。
Zotero 插件